Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 20 of 93« First...10...1819202122...304050...Last »

Roche’s Alecensa notches trial win against Pfizer’s Xalkori

Roche’s Alecensa kept people with a specific lung cancer alive longer without their disease progressing than Xalkori as it seeks to move in on Pfizer’s share of early treatment of the disease.

Read More »

Takeda study brings dengue vaccine step closer

Takeda Pharmaceutical completed enrollment for a 20,000-subject dengue vaccine trial, the largest clinical study in the company’s history.

Read More »

Common antibiotic could prevent or treat PTSD

A common antibiotic called doxycycline can disrupt the formation of negative thoughts and fears in the brain and may prove useful in treating or preventing post traumatic stress disorder (PTSD), according to research by British and Swiss scientists.

Read More »

Immunotherapy combo extends melanoma survival

Patients with advanced melanoma who received Bristol-Myers Squibb’s immunotherapies Opdivo and Yervoy had improved overall survival versus those on Yervoy alone.

Read More »

Vertex CF combo succeeds in late-stage trials

Vertex Pharmaceuticals Inc. said its Kalydeco cystic fibrosis treatment given with an experimental drug demonstrated significant improvements in lung function in a pair of late-stage trials the company plans to use to seek approval of the combination therapy.

Read More »

Foamix’s acne drug misses main goal in key study

Foamix Pharmaceuticals Ltd. said its experimental acne treatment failed to meet one of two main goals in a late-stage study, pushing its shares down about 42 percent.

Read More »

Ultragenyx Seizure Drug Flunks Phase II Test

Shares of Ultragenyx Pharmaceuticals were down after the company announced its Phase II drug UX007 to treat seizures failed to meet trial goals.

Read More »

GSK and Regeneron to mine gene data

GlaxoSmithKline and Regeneron Pharmaceuticals are embarking on a joint project with UK Biobank to hunt for new clues linking genes and disease.

Read More »

Novartis heart drug serelaxin fails study

Novartis’ heart failure drug serelaxin flopped in a late-stage trial by not cutting cardiovascular death or slowing disease progression, marking the likely demise of a drug hopeful the Swiss firm had promoted as a potential blockbuster.

Read More »

Breast cancer drug combo succeeds key study

Eli Lilly and Co.’s combination of its experimental breast cancer drug abemaciclib and another widely used treatment slowed disease progression.

Read More »

Nektar’s opioid painkiller succeeds in key study

Nektar Therapeutics said its experimental opioid succeeded in a key late-stage study.

Read More »

Catalyst’s neuromuscular drug succeeds in study

Catalyst Pharmaceuticals Inc.’s experimental drug to treat patients with a severe form of myasthenia gravis, a rare neuromuscular disease, met the main goals of a study.

Read More »

FDA Grants Orphan Drug Designation to CSRA’s DynPort Vaccine Company for Plague Vaccine

DynPort’s clinical stage recombinant Yersinia pestis rF1V plague vaccine to benefit from FDA Orphan Drug Designation FALLS CHURCH, Va., March 8, 2017 /PRNewswire/ — CSRA Inc. (NYSE: CSRA) today announced that a plague vaccine being developed by its subsidiary, DynPort Vaccine Company LLC (DVC), was granted Orphan Drug Designation from the U.S. Food and Drug Administration […]

Read More »

Precision Medicine: What Is It And Why Now?

Nearly two decades ago, the promise of precision medicine began making its mark on the pages of medical journals – along with speculation that “therapy with the right drug at the right dose in the right patient” – would define the future of medical treatment.

Read More »

Latest Dupixent eczema drug tests positive

Sanofi and Regeneron said results from a one-year test of Dupixent aimed at adults with eczema or moderate-to-severe atopic dermatitis had been positive.

Read More »

Guselkumab Outperforms Humira In Study

Study data showed patients treated with guselkumab experienced significantly greater improvements compared with the anti-TNF-alpha treatment Humira.

Read More »

Chi-Med Shows Off Phase III Cancer Drug Data

Chi-Med’s fruquintinib met all main endpoints in a Phase III trial as a third-line treatment in patients with locally advanced or metastatic colorectal cancer.

Read More »

PTC abandons cystic fibrosis drug after trial failure

PTC Therapeutics Inc. said it would stop developing its cystic fibrosis drug after it failed to meet the main goal of a late-stage study.

Read More »

Roche drug cocktail cuts breast cancer deaths

Roche’s bid to shield its lucrative oncology franchise from generics got a lift from a trial showing a new drug cocktail kept breast cancer patients alive longer.

Read More »

Kite’s cancer drug clears main study goal

Kite Pharma Inc.’s experimental CAR T-cell therapy was highly effective in treating aggressive non-Hodgkin’s lymphoma, meeting the main goal of a key study.

Read More »

Page 20 of 93« First...10...1819202122...304050...Last »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!


Ad Right Bottom